Compare Okta, Inc. (OKTA) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Okta, Inc. vs Spyre Therapeutics Inc. Common Stock — how do they compare? Okta, Inc. trades at $205.94 (market cap $39.60B), while Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.52B). The key difference: Okta, Inc. is far larger — about 5.3× Spyre Therapeutics Inc. Common Stock's market cap, and Okta, Inc. is trading nearer its 52-week high, Spyre Therapeutics Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Okta, Inc. for 44 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| OKTA | SYRE | |
|---|---|---|
Market Cap | $39.60B | $7.52B |
Volume | 2,315,203 | 1,441,031 |
Sector | Technology | Health |
52-Week High | $232.13 | $108.92 |
52-Week Low | $62.93 | $22.18 |
Typical Hold Time | 44 Days | 0 Days |
Enterprise Value | $37.36B | $6.52B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
OKTA trades at $211.92, down 6.68% today, but maintains strong analyst support with 74% buy ratings and a consensus price target of $201.76. The company has beaten earnings estimates for three consecutive quarters, with Q3 2026 EPS expected at $0.93. Revenue growth remains robust, climbing from $1.3B in 2022 to $2.6B in 2025, while achieving positive net income of $28M after years of losses. Technical indicators show a bullish trend with key support at $215.
OKTA presents a compelling growth story with improving profitability and strong positioning in identity management. The stock faces valuation concerns with a P/E of 136, but AI security initiatives and consistent earnings beats provide catalysts. Key risks include high valuation multiples and competitive pressures in cybersecurity.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Okta, Inc.
Okta is a cloud-native security company that focuses on identity and access management. The San Francisco-based firm went public in 2017 and focuses on two key client stakeholder groups: workforces and customers. Okta's workforce offerings enable a company's employees to securely access its cloud-based and on-premises resources. The firm's customer offerings allow its clients' customers to securely access the client's applications.
Read more on OKTA →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
